Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

被引:700
作者
Yauch, Robert L. [1 ]
Dijkgraaf, Gerrit J. P. [1 ]
Alicke, Bruno [1 ]
Januario, Thomas [1 ]
Ahn, Christina P. [1 ]
Holcomb, Thomas [1 ]
Pujara, Kanan [1 ]
Stinson, Jeremy [1 ]
Callahan, Christopher A. [1 ]
Tang, Tracy [1 ]
Bazan, J. Fernando [1 ]
Kan, Zhengyan [1 ]
Seshagiri, Somasekar [1 ]
Hann, Christine L. [2 ]
Gould, Stephen E. [1 ]
Low, Jennifer A. [1 ]
Rudin, Charles M. [2 ]
de Sauvage, Frederic J. [1 ]
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
关键词
PROTEIN-COUPLED RECEPTORS; CYCLOPAMINE; CANCER;
D O I
10.1126/science.1179386
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The Hedgehog (Hh) signaling pathway is inappropriately activated in certain human cancers, including medulloblastoma, an aggressive brain tumor. GDC-0449, a drug that inhibits Hh signaling by targeting the serpentine receptor Smoothened (SMO), has produced promising anti-tumor responses in early clinical studies of cancers driven by mutations in this pathway. To evaluate the mechanism of resistance in a medulloblastoma patient who had relapsed after an initial response to GDC-0449, we determined the mutational status of Hh signaling genes in the tumor after disease progression. We identified an amino acid substitution at a conserved aspartic acid residue of SMO that had no effect on Hh signaling but disrupted the ability of GDC-0449 to bind SMO and suppress this pathway. A mutation altering the same amino acid also arose in a GDC-0449-resistant mouse model of medulloblastoma. These findings show that acquired mutations in a serpentine receptor with features of a G protein-coupled receptor can serve as a mechanism of drug resistance in human cancer.
引用
收藏
页码:572 / 574
页数:3
相关论文
共 16 条
[1]   Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened [J].
Chen, JK ;
Taipale, J ;
Cooper, MK ;
Beachy, PA .
GENES & DEVELOPMENT, 2002, 16 (21) :2743-2748
[2]   The hedgehog pathway and neurological disorders [J].
Dellovade, Tammy ;
Romer, Justyna T. ;
Curran, Tom ;
Rubin, Lee L. .
ANNUAL REVIEW OF NEUROSCIENCE, 2006, 29 :539-563
[3]   G-protein-coupled receptors and cancer [J].
Dorsam, Robert T. ;
Gutkind, J. Silvio .
NATURE REVIEWS CANCER, 2007, 7 (02) :79-94
[4]   Altered neural cell fates and medulloblastoma in mouse patched mutants [J].
Goodrich, LV ;
Milenkovic, L ;
Higgins, KM ;
Scott, MP .
SCIENCE, 1997, 277 (5329) :1109-1113
[5]  
Goudet C., 2004, DRUG DISCOV TODAY TH, V1, P125
[6]   Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade [J].
Hyman, Joel M. ;
Firestone, Ari J. ;
Heine, Vivi M. ;
Zhao, Yun ;
Ocasio, Cory A. ;
Han, Kyuho ;
Sun, Mark ;
Rack, Paul G. ;
Sinha, Surajit ;
Wu, Jason J. ;
Solow-Cordero, David E. ;
Jiang, Jin ;
Rowitch, David H. ;
Chen, James K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (33) :14132-14137
[7]   First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting [J].
Molckovsky, Andrea ;
Siu, Lillian L. .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2008, 1 (1)
[8]   Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification [J].
Polkinghorn, William R. ;
Tarbell, Nancy J. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (05) :295-304
[9]   Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/- p53-/- mice [J].
Romer, JT ;
Kimura, H ;
Magdaleno, S ;
Sasai, K ;
Fuller, C ;
Baines, H ;
Connelly, M ;
Stewart, CF ;
Gould, S ;
Rubin, LL ;
Curran, T .
CANCER CELL, 2004, 6 (03) :229-240
[10]   The structure and function of G-protein-coupled receptors [J].
Rosenbaum, Daniel M. ;
Rasmussen, Soren G. F. ;
Kobilka, Brian K. .
NATURE, 2009, 459 (7245) :356-363